New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
04:55 EDTACHC, ACHC, ACHC, BABY, BABY, BABY, CNC, CNC, CNC, INCY, INCY, INCY, AUXL, AUXL, AUXL, HGR, HGR, HGR, ALKS, ALKS, ALKS, ACHN, ACHN, ACHN, MZOR, MZOR, MZOR, LMNX, LMNX, LMNX, IDIX, IDIX, IDIXUBS to hold a conference
Global Healthcare Conference to be held in New York on May 19-21.
News For IDIX;LMNX;MZOR;ACHN;ALKS;HGR;AUXL;INCY;CNC;BABY;ACHC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2015
07:12 EDTALKSAlkermes raises FY15 adjusted EPS view to (31c)-(45c) from (37c)-(50c)
Subscribe for More Information
07:10 EDTALKSAlkermes reports Q2 adjusted EPS (9c), consensus (10c)
Subscribe for More Information
July 29, 2015
16:59 EDTCNCHealth Net cancels conference call, webcast
Health Net (HNT) announced that, as a result of the July 2, announcement that Health Net and Centene (CNC) approved a definitive agreement under which Centene will acquire all of the shares of Health Net in a cash and stock transaction valued at approximately $6.8B, including the assumption of approximately $500M of debt, Health Net is cancelling its previously scheduled Q2 earnings conference call and webcast. The call was previously scheduled for August 4, at 12:00 noon Eastern time. Health Net intends to issue a press release reporting the company’s financial results for Q2, as planned, before the market opens on Tuesday, August 4. The company expects to file its Quarterly Report on Form 10-Q for the quarter ended June 30 with the SEC on or about August 5.
15:08 EDTALKSNotable companies reporting before tomorrow's open
Subscribe for More Information
13:54 EDTALKSEarnings Watch: Alkermes up around 17% since last earnings report
Alkermes (ALKS) is scheduled to report second quarter earnings before the market open on Thursday, July 30 with a conference call scheduled for 8:30 am ET. Alkermes, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. EXPECTATIONS: Analysts are looking for a loss of (10c) per share on revenue of $142.8M, according to First Call. The consensus range for EPS is for a loss of (17c)-(4c) on revenue of $134.5M-$153.28M. LAST QUARTER: Alkermes reported first quarter EPS of 6c, compared to a consensus estimate of a loss of (3c), on revenue of $161.2M against estimates of $146.6M. The company reiterated all of its financial expectations for 2015 that it had previously given on March 9, when it cut its 2015 EPS view to (37c)-(50c) from (27c)-(40c). Q1 revenue from the company's anti-psychotic franchise, including Risperdal were $46.9M, compared to $49.6M for the same period in the prior year. Revenues from Amprya/Famprya were $36.5M, compared to $20.6M for the same period in the prior year. "Our results this quarter reflect strong revenues from our portfolio of key commercial products and focused investment in our promising late-stage pipeline of CNS product candidates that will drive our future growth," commented Alkermes CFO James Frates. Alkermes CEO Richard Pops noted that the company is on the "threshold" of its next growth phase and that Aripiprazole lauroxil, the company's long-acting atypical anti-psychotic for schizophrenia, is moving toward FDA approval and launch later this year. STREET RESEARCH: On June 26, Cowen said the clinical profile for Alkermes' ALKS 3831 continues to look interesting, as the firm's consultants believe data for the drug suggests a profile that would provide a significant benefit over Zyprexa for the treatment of schizophrenia. Cowen reiterated its Outperform rating and $80 price target on Alkermes shares. PRICE ACTION: Alkermes shares are up around 17% since the company's last earnings report on April 30, and are down almost 3% to $67.40 in midday trading ahead of Thursday's earnings release.
09:12 EDTCNCCentene has reached attractive entry point, says BMO Capital
Subscribe for More Information
July 28, 2015
06:11 EDTCNCCentene sees FY15 EPS $2.72-$2.82, consensus $2.79
Subscribe for More Information
06:10 EDTCNCCentene reports Q2 EPS 72c, consensus 70c
Subscribe for More Information
05:44 EDTMZORMazor Robotics reports Q2 non-GAAP EPS (4c), consensus (13c)
Reports Q2 revenue $7.80M, consensus $6.47M. Reports Q2 US revenue $6.5M.
July 27, 2015
10:40 EDTALKSLeerink major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
10:00 EDTCNCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ADT Corp. (ADT) upgraded to Buy from Neutral at Citi... AGCO (AGCO) upgraded to Neutral from Sell at Goldman... Anthem (ANTM) upgraded to Buy from Neutral at Sterne Agee CRT... BNP Paribas (BNPQY) upgraded to Buy from Neutral at Goldman... Biogen (BIIB) upgraded on valuation at Bernstein... Box (BOX) upgraded to Overweight from Sector Weight at Pacific Crest... Capital One (COF) upgraded to Buy from Outperform at CLSA... Centene (CNC) upgraded to Buy from Neutral at UBS... Chesapeake (CHK) upgraded on potential sale of assets or company at SunTrust... Cigna (CI) upgraded to Buy from Neutral at Sterne Agee CRT... Deere (DE) upgraded to Neutral from Sell at Goldman... First BanCorp (FBP) upgraded to Buy from Neutral at Guggenheim... Flotek (FTK) upgraded on stronger demand at Oppenheimer... Lear (LEA) upgraded to Buy from Hold at Deutsche Bank... Methanex (MEOH) upgraded to Outperform from Sector Perform at Scotia Howard Weil... News Corp. (NWSA) upgraded to Outperform from Neutral at Macquarie... NextEra Energy Partners (NEP) upgraded to Outperform at Wells Fargo... OFG Bancorp (OFG) upgraded to Buy from Neutral at Guggenheim... PennyMac Mortgage (PMT) upgraded to Buy from Neutral at Compass Point... Pool Corp. (POOL) upgraded to Outperform from Market Perform at William Blair... Popular (BPOP) upgraded to Buy from Neutral at Guggenheim... Qualcomm (QCOM) upgraded to Overweight from Equal Weight at Morgan Stanley... Quality Systems (QSII) upgraded on valuation at RBC Capital... VF Corp. (VFC) upgraded to Buy from Neutral at Goldman... Ventas (VTR) upgraded on valuation, positive catalysts at BMO Capital... Weatherford (WFT) upgraded to Equal Weight from Underweight at Barclays... SS&C (SSNC) upgraded to Buy from Hold at Sandler O'Neill... Chemung Financial (CHMG) upgraded to Buy from Hold at Sandler O'Neill... Cameron (CAM) upgraded to Buy from Accumulate at Global Hunter.
07:33 EDTCNCCentene upgraded to Buy from Neutral at UBS
UBS upgraded Centene to Buy from Neutral citing recent share weakness, its strong pipeline and other underappreciated opportunities. UBS maintained its $80 price target on Centene shares.
July 23, 2015
09:21 EDTBABYNatus Medical price target raised to $51 from $45 at Roth Capital
Subscribe for More Information
July 22, 2015
09:41 EDTLMNXEnzo Biochem reaches patent infringement settlement with Siemens Healthcare
Subscribe for More Information
08:47 EDTCNCCentene weakness creates buying opportunity, says BMO Capital
BMO Capital believes that Centene's (CNC) earnings can increase 24% year-over-year in the near-term, driven by predictable levels of medical cost and continued membership growth. Over the longer term, the firm thinks that the company's acquisition of HealthNet (HNT), large addressable markets, cost synergies and improved positioning in California leave it well-positioned to increase its earnings.
06:08 EDTBABYNatus Medical raises FY15 non-GAAP EPS view to $1.50-$1.52 from $1.47-$1.51
Subscribe for More Information
06:07 EDTBABYNatus Medical sees Q3 non-GAAP EPS 37c-38c, consensus 39c
Subscribe for More Information
06:05 EDTBABYNatus Medical reports Q2 non-GAAP EPS 34c, consensus 32c
Reports Q2 revenue $91.9M, consensus $90.83M. Reports Q2 constant currency revenue $93.4M after adjusting for a $1.5M foreign currency impact.
July 21, 2015
10:01 EDTCNCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:28 EDTCNCCentene downgraded to Sell from Neutral at Goldman
Goldman downgraded Centene (CNC) to Sell with a $69 price target. The firm's analyst believes Centene's acquisition of Health Net (HNT) is a signal of slower organic growth and makes the company a less likely M&A target. Goldman sees increasing execution risk given complex deal integration and lowered its price target to $69 from $73 on shares.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use